Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Sunitinib
Treatment for Kidney cancer
Typical Dosage: 50 mg oral once daily (4 weeks on, 2 weeks off cycle)
Effectiveness
65%
Safety Score
30%
Clinical Trials
241
Participants
1.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
50 mg oral once daily (4 weeks on, 2 weeks off cycle)
Time to Effect
Weeks to months
Treatment Duration
Until disease progression or unacceptable toxicity (4 weeks on, 2 weeks off cycle)
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$15,000
Side Effect Mgmt:$10,000
Total Annual:$145,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
0.82
Outcome-Based Costs
Cost per Responder
$467,742
Cost per Remission
$7,250,000
Comparison vs Interferon-alpha
Cost Difference
+$50,000/year
More expensive
QALY Difference
+0.82 QALYs
Better outcomes
Dominance
No dominance
Sunitinib Outcomes
for Kidney cancer
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+31%
Remission Rate
+2%
Common Side Effects
Fatigue
+65%
Diarrhea
+59%
Nausea
+44%
Mucositis/Stomatitis
+43%
Hand-foot syndrome
+40%
Hypertension
+31%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Sunitinib in Kidney cancer
A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment
NCT02688491NOT YET RECRUITINGNA
300 participants
INTERVENTIONAL
Started: Jul 1, 2016
Completed Clinical Trials
18 completed trials for Sunitinib in Kidney cancer
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
NCT03109015COMPLETEDPHASE2
7 participants
INTERVENTIONAL
Durham, United States
Started: Sep 27, 2017
Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.
NCT03066427COMPLETEDPHASE2
23 participants
INTERVENTIONAL
L'Hospitalet de Llobregat, Spain +8 more
Started: May 10, 2017
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
NCT00372853COMPLETEDPHASE1
28 participants
INTERVENTIONAL
Scottsdale, United States +4 more
Started: Nov 1, 2006
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
NCT04669366COMPLETED
1.21K participants
OBSERVATIONAL
Sollentuna, Sweden
Started: Jan 20, 2021
Sunitinib in Metastatic Renal Cancer
NCT01034878COMPLETEDPHASE2
25 participants
INTERVENTIONAL
Rozzano, Italy
Started: Dec 1, 2009
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974COMPLETEDPHASE2
106 participants
INTERVENTIONAL
Duarte, United States +14 more
Started: Feb 1, 2004
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
NCT00399152COMPLETEDPHASE1
15 participants
INTERVENTIONAL
Started: Oct 1, 2006
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer
NCT00375674COMPLETEDPHASE3
674 participants
INTERVENTIONAL
Los Angeles, United States +114 more
Started: Aug 1, 2007
Safety And Effectiveness Of Daily Dosing With 37.5 mg Sunitinib Malate In Patients With Advanced Kidney Cancer
NCT00338884COMPLETEDPHASE2
120 participants
INTERVENTIONAL
Córdoba, Argentina +14 more
Started: Sep 1, 2006
ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib
NCT03097601COMPLETED
60 participants
OBSERVATIONAL
Nice, France
Started: Jun 2, 2016
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
NCT00716625COMPLETED
1.67K participants
OBSERVATIONAL
Started: Jun 1, 2008
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
NCT00706706COMPLETEDPHASE4
105 participants
INTERVENTIONAL
Guangzhou, China +10 more
Started: Jul 1, 2008
SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
NCT00089648COMPLETEDPHASE2
61 participants
INTERVENTIONAL
Duarte, United States +10 more
Started: Dec 1, 2004
Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer
NCT00465179COMPLETEDPHASE2
61 participants
INTERVENTIONAL
Houston, United States
Started: Mar 1, 2007
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
NCT00891475COMPLETEDPHASE1, PHASE2
114 participants
INTERVENTIONAL
Moscow, Russia
Started: May 1, 2008
Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
NCT00663559COMPLETEDPHASE2
59 participants
INTERVENTIONAL
Barcelona, Spain +6 more
Started: Feb 1, 2008
Study of SU011248 in Patients With Advanced Kidney Cancer
NCT00254540COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Akita, Japan +10 more
Started: Dec 1, 2005
Study In Patients With Kidney Cancer Treated With Sutent
NCT00873210COMPLETED
121 participants
OBSERVATIONAL
Banská Bystrica, Slovakia +13 more
Started: May 1, 2009
Showing 20 of 241 total trials